Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanil Bhatia

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Expert Opinion on Drug Discovery|August 27, 2016
Mouse models for pre-clinical drug testing in leukemiaSanil Bhatia, Svenja Daschkey, Franziska Lang, et al.
Frontiers in Immunology|June 6, 2018
Interleukin-2-Inducible T-Cell Kinase Deficiency-New Patients, New Insight?Sujal Ghosh, Ingo Drexler, Sanil Bhatia, et al.
Frontiers in Immunology|October 17, 2018
Corrigendum: Interleukin-2-Inducible T-Cell Kinase Deficiency-New Patients, New Insight?Sujal Ghosh, Ingo Drexler, Sanil Bhatia, et al.
Molecular & Cellular Oncology|September 26, 2018
T-cell leukemogenesis is an inappropriate lineage decision-making process: implications for precision oncologyGuillermo Rodríguez-Hernández, Sanil Bhatia, Carolina Vicente-Dueñas, et al.
Frontiers in Chemistry|July 14, 2023
Development of the first geldanamycin-based HSP90 degradersSilas Wurnig, Melina Vogt, Julian Hogenkamp, et al.
European Journal of Medical Genetics|December 3, 2015
GEMMs addressing Pax5 loss-of-function in childhood pB-ALLFranziska Auer, Deborah Ingenhag, Sanil Bhatia, et al.
Cancers|October 3, 2020
Senescent Tumor CD8<sup>+</sup> T Cells: Mechanisms of Induction and Challenges to ImmunotherapyWei Liu, Paweł Stachura, Haifeng C Xu, et al.
Scientific Reports|May 21, 2025
Identification of non-charged 7.44 analogs interacting with the NHR2 domain of RUNX1-ETO with improved antiproliferative effect in RUNX-ETO positive cellsMohanraj Gopalswamy, David Bickel, Niklas Dienstbier, et al.
ACS Medicinal Chemistry Letters|July 14, 2026
Targeting Histone Acetyltransferases EP300/CBP by Novel Proline-Based PROTAC DegradersKathrin Tan, Melina Vogt, Katerina Schaal, et al.
Cancer Immunology, Immunotherapy : CII|August 16, 2021
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALLSarah B Reusing, Dan A Vallera, Angela R Manser, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Expert Opinion on Drug Discovery|August 27, 2016
Mouse models for pre-clinical drug testing in leukemiaSanil Bhatia, Svenja Daschkey, Franziska Lang, et al.
Frontiers in Immunology|June 6, 2018
Interleukin-2-Inducible T-Cell Kinase Deficiency-New Patients, New Insight?Sujal Ghosh, Ingo Drexler, Sanil Bhatia, et al.
Frontiers in Immunology|October 17, 2018
Corrigendum: Interleukin-2-Inducible T-Cell Kinase Deficiency-New Patients, New Insight?Sujal Ghosh, Ingo Drexler, Sanil Bhatia, et al.
Molecular & Cellular Oncology|September 26, 2018
T-cell leukemogenesis is an inappropriate lineage decision-making process: implications for precision oncologyGuillermo Rodríguez-Hernández, Sanil Bhatia, Carolina Vicente-Dueñas, et al.
Frontiers in Chemistry|July 14, 2023
Development of the first geldanamycin-based HSP90 degradersSilas Wurnig, Melina Vogt, Julian Hogenkamp, et al.
European Journal of Medical Genetics|December 3, 2015
GEMMs addressing Pax5 loss-of-function in childhood pB-ALLFranziska Auer, Deborah Ingenhag, Sanil Bhatia, et al.
Cancers|October 3, 2020
Senescent Tumor CD8<sup>+</sup> T Cells: Mechanisms of Induction and Challenges to ImmunotherapyWei Liu, Paweł Stachura, Haifeng C Xu, et al.
Scientific Reports|May 21, 2025
Identification of non-charged 7.44 analogs interacting with the NHR2 domain of RUNX1-ETO with improved antiproliferative effect in RUNX-ETO positive cellsMohanraj Gopalswamy, David Bickel, Niklas Dienstbier, et al.
ACS Medicinal Chemistry Letters|July 14, 2026
Targeting Histone Acetyltransferases EP300/CBP by Novel Proline-Based PROTAC DegradersKathrin Tan, Melina Vogt, Katerina Schaal, et al.
Cancer Immunology, Immunotherapy : CII|August 16, 2021
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALLSarah B Reusing, Dan A Vallera, Angela R Manser, et al.
Pageof 6